Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

Phase 1

Terminated

Conditions: Stage IV Rectal Cancer
Recurrent Rectal Cancer
Recurrent Colon Cancer
Stage IV Colon Cancer

Interventions: Drug: panobinostat
Drug: fluorouracil
Drug: leucovorin calcium
Procedure: biopsy
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: western blotting
Other: laboratory biomarker analysis
Genetic: gene expression analysis
Genetic: RNA analysis
Genetic: polymorphism analysis

First Posted Date: 2010-11-11

Last Posted Date: 2015-05-27

Lead Sponsor: University of Southern California

Target Recruit Count: 7

Registration Number: NCT01238965

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Eniluracil
Drug: 5-Fluorouracil
Drug: Leucovorin

First Posted Date: 2010-11-01

Last Posted Date: 2012-07-17

Lead Sponsor: Adherex Technologies, Inc.

Target Recruit Count: 140

Registration Number: NCT01231802

Locations: 🇷🇺
Chelyabinsk Regional Clinical Oncology, Chelyabinsk, Russian Federation
🇷🇺
Republic Oncology Center, Republic of Karelia, Russian Federation
🇷🇺
Stavropol Regional Clinical Oncology Center, Stavropol, Russian Federation

and more 13 locations

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Phase 1

Completed

Conditions: Diffuse Adenocarcinoma of the Stomach
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Intestinal Adenocarcinoma of the Stomach
Recurrent Esophageal Cancer
Stage IV Esophageal Cancer
Stage IV Gastric Cancer
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: everolimus
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Genetic: microarray analysis

First Posted Date: 2010-11-01

Last Posted Date: 2017-05-31

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 6

Registration Number: NCT01231399

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
South Pasadena Cancer Center, South Pasadena, California, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Phase 2

Terminated

Conditions: Localized Unresectable Adult Primary Liver Cancer
Periampullary Adenocarcinoma
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Recurrent Extrahepatic Bile Duct Cancer
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: cediranib maleate
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2010-10-27

Last Posted Date: 2017-03-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT01229111

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Lake University Ireland Cancer Center, Mentor, Ohio, United States
🇺🇸
UHHS-Chagrin Highlands Medical Center, Orange Village, Ohio, United States

and more 4 locations

A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: capecitabine [Xeloda]
Radiation: Radiation therapy
Procedure: Mesorectal excision
Drug: 5-fluorouracil
Drug: leucovorin

First Posted Date: 2010-10-25

Last Posted Date: 2015-08-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT01227707

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Panitumumab
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2010-10-22

Last Posted Date: 2015-05-27

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 15

Registration Number: NCT01226719

Locations: 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Hope Cancer Center, Terre Haute, Indiana, United States

and more 11 locations